One-way sensitivity analysis for stable population
| Cost difference (£) | QALY difference | ICER (£/QALY) | Probability cost-effective* | |
| Varying the rate ratio | ||||
| Best-case NIV | +£8804 | +0.562 | £15 665 | 99.2% |
| Worst-case NIV | +£8112 | −0.111 | Dominated | 0% |
| Base case | +£8488 | +0.310 | £27 380 | 4% |
| Best-case ‘Western’ setting NIV† | +£8812 | +0.271 | £31 196 | 8% |
| Worst-case ‘Western’, setting NIV† | +£8112 | −0.111 | Dominated | 0% |
| Change in utility on NIV | ||||
| +0.20 utility | +£8488 | +1.147 | £7401 | 100% |
| +0.10 utility | +£8488 | +0.72 | £11 597 | 100% |
| +0.05 utility | +£8488 | +0.514 | £16 514 | 82.4% |
| Base case | +£8488 | +0.310 | £27 380 | 4% |
| −0.05 | +£8488 | +0.097 | £87 505 | 0% |
| Varying duration of effect | ||||
| 2 years | +£8488 | +0.150 | £56 153 | 0% |
| 10 years (model horizon) | +£7896 | +0.413 | £19 119 | 58% |
| Alternate model time horizon | ||||
| 2 years | +£2057 | +0.033 | £62 333 | 0% |
| 15 years | +£10 696 | +0.392 | £27 286 | 3% |
| 20 years | +£11 750 | +0.429 | £27 389 | 3% |
| Alternate mortality and readmission risk | ||||
| Higher risks from Garcia-Aymerich et al 12 | +£5137 | +0.247 | £20 797 | 44% |
*Cost-effective at £20 000/QALY.
†Western studies included studies reporting hospitalisations from Italy, Poland, The Netherlands, Germany and the UK
ICER, incremental cost-effectiveness ratio; NIV, non-invasive ventilation; QALY, quality-adjusted life year.